Asian Women with Endocrine-Resistant Breast Cancer Benefit from Combination Therapy
Promising results of PALOMA3 trial confirmed in Asian patients
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Promising results of PALOMA3 trial confirmed in Asian patients
Phase I trial reports that pembrolizumab is active in nasopharyngeal cancer. Afatinib is effective as second-line treatment in squamous cell carcinoma of the head and neck in a Phase II study
Underprivileged patients are at major risk of disease-related “financial catastrophe", study in eight low- and middle-income Southeast Asian countries shows
LUGANO/SINGAPORE, 16 December 2015 – ESMO, the leading professional organisation for medical oncology, is pleased to announce the inaugural ESMO Asia 2015 Congress in Singapore. A premier scientific and educational platform for oncologists and other stakeholders in cancer care, the Asian edition of ESMO’s annual congress aims to facilitate information exchange between researchers, clinicians and patients across disciplines to find the most effective treatment solutions.
CheckMate 017 clearly showed that the checkpoint inhibitor improves the overall health status in patients with advanced squamous non-small-cell lung cancer
Two drugs are changing the current landscape for the treatment of advanced renal cell carcinoma
Cancer is distressing for patients and families, and supportive care is today an important part of therapy
Gastric cancer (GC) is one of the most aggressive oncologic diseases, with a 5 year median survival of 25%. Surgery remains the only curative option, although with a high recurrence rate.
Novel approaches and drugs are showing promising results in solid cancers.
A small study presented at ECC2015 shows positive responses in patients with Merkel cell carcinoma after few weeks of treatment with checkpoint inhibitors
The genomic landscape of lung cancer is becoming clearer as new mutations are identified in different types of cancers. Two studies presented at the European Cancer Congress (ECC) 2015 in Vienna report new insights into this expanding area.
Loss of fertility is a primary concern for some breast cancer patients as 10% of breast cancers occur in women younger than 40 years of age. Chemotherapy destroys rapidly dividing cells and the ovaries can be sensitive to this.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.